Source link : https://www.newshealth.biz/health-news/kinder-gentler-regimen-for-classical-hodgkin-prevails-in-randomized-trial/
CHICAGO — Replacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced classical Hodgkin lymphoma (cHL) with no loss in efficacy, according to a randomized study reported. The estimated 4-year progression-free survival (PFS) was 94.3% with brentuximab vedotin (Adcetris) versus 90.9% with the conventional BEACOPP regimen. The 4-year overall survival (OS) […]
Author : News Health
Publish date : 2024-06-01 18:41:12
Copyright for syndicated content belongs to the linked Source.
Categories